CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab

Here, we report on a novel bispecific antibody-derivative, designated RTX-CD47, with unique capacity for CD20-directed inhibition of CD47-SIRPα “don't eat me” signaling. RTX-CD47 comprises a CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv. Si...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: van Bommel, Peter E., He, Yuan, Schepel, Ilona, Hendriks, Mark A. J. M., Wiersma, Valerie R., van Ginkel, Robert J., van Meerten, Tom, Ammatuna, Emanuele, Huls, Gerwin, Samplonius, Douwe F., Helfrich, Wijnand, Bremer, Edwin
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5749665/
https://ncbi.nlm.nih.gov/pubmed/29308308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1386361
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados